A206650 Stock Overview
A biopharmaceutical company, provides vaccines for epidemics in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
EuBiologics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,690.00 |
| 52 Week High | ₩14,500.00 |
| 52 Week Low | ₩8,310.00 |
| Beta | 1.35 |
| 11 Month Change | 3.00% |
| 3 Month Change | -4.02% |
| 1 Year Change | 13.83% |
| 33 Year Change | -72.00% |
| 5 Year Change | 84.38% |
| Change since IPO | 130.57% |
Recent News & Updates
Investors Holding Back On EuBiologics Co., Ltd. (KOSDAQ:206650)
Aug 12
Is EuBiologics (KOSDAQ:206650) A Risky Investment?
May 30Shareholder Returns
| A206650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.5% | 1.5% | 1.9% |
| 1Y | 13.8% | 38.5% | 5.0% |
Return vs Industry: A206650 underperformed the KR Biotechs industry which returned 38.5% over the past year.
Return vs Market: A206650 exceeded the KR Market which returned 5% over the past year.
Price Volatility
| A206650 volatility | |
|---|---|
| A206650 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A206650 has not had significant price volatility in the past 3 months.
Volatility Over Time: A206650's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 291 | Yeong-Ok Baik | www.eubiologics.com |
EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits.
EuBiologics Co., Ltd. Fundamentals Summary
| A206650 fundamental statistics | |
|---|---|
| Market cap | ₩426.50b |
| Earnings (TTM) | -₩13.88b |
| Revenue (TTM) | ₩69.37b |
6.1x
P/S Ratio-30.7x
P/E RatioIs A206650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A206650 income statement (TTM) | |
|---|---|
| Revenue | ₩69.37b |
| Cost of Revenue | ₩35.40b |
| Gross Profit | ₩33.96b |
| Other Expenses | ₩47.84b |
| Earnings | -₩13.88b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -380.41 |
| Gross Margin | 48.96% |
| Net Profit Margin | -20.01% |
| Debt/Equity Ratio | 11.7% |
How did A206650 perform over the long term?
See historical performance and comparison